Germany Pharmaceuticals and Healthcare Report Q4 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Refresh your vocabulary. Learn a new word everyday by subscribing to Word of the Day. A great tool if you're studying for the GRE, GMAT or LSAT, or simply want to enhance your lexicon. From our sponsors

Germany Pharmaceuticals and Healthcare Report Q4 2013 Aug 21st 2013, 00:00, by rnrmahesh BMI View: The Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) legislation will constrict drug companies’ revenue-earning opportunities in Germany. While the law has focussed on the regulation of the pricing of newly approved drugs relative to their benefit over already-existing therapies – hitting companies hard – the government is now clamping down on prices set by drug companies back in Germany’s free pricing era. Headline Expenditure Projections ? Pharmaceuticals: EUR38.89bn (US$49.39bn) in 2012 to EUR37.93bn (US$50.45bn) in 2013; -2.5% in local currency terms and 2.2% in US dollar terms. ? Healthcare: EUR291.82bn (US$3970.61bn) in 2012 to EUR297.32bn (US$395.43bn) in 2013; +1.9% in local currency terms … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=111945. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/germany-pharmaceuticals-and-healthcare-report-q4-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions